Awarded
Abschluss einer nicht-exklusiven Rabattvereinbarung nach § 130a Abs. 8 SGB V zum Wirkstoff Rivaroxaban, ATC B01AF01 für die Zeit 01.04.2026 - 30.06.2026
Original language: German
Track this recordWith Adjudera Pro, get alerted before a contract here runs out.
- Buyer
- DAK-Gesundheit
- Winners
- 089PHARM GmbH, 1 A Pharma GmbH, AAA Pharma GmbH, Abdi Farma GmbH, AbZ-Pharma GmbH, Accord Healthcare S.L.U., axcount Generika GmbH, betapharm Arzneimittel GmbH, BG ALIUD / STADAPHARM GbR, Cipla Europe NV, Glenmark Arzneimittel GmbH, Heumann Pharma GmbH & Co. Generica KG, ratiopharm GmbH, TAD Pharma GmbH, Vivanta Generics s.r.o., Zentiva Pharma GmbH
- Contract value
- no value published
- Bids received
- 26
- Published
- 31 Aug 2026
- Awarded
- 1 Apr 2026
- Contract start
- 1 Apr 2026
- Contract end
- 14 Apr 2027estimated
- Region
- Hamburg